LGALS9

Across TCGA pan-cancer cohorts, LGALS9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LGALS9 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LGALS9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LGALS9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and GBM are the cancer types where LGALS9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.854	0.334	.008	14	view →
HNSC	DFS	Quartile	All	0.927	1.000	.036	4	view →
GBM	DFS	Median	All	0.482	0.267	.030	2	view →
CCRCC	DFS	Quartile	III,IV	0.420	0.771	.046	2	view →
PDAC	DFS	Median	All	0.877	0.711	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LGALS9–LUAD (DFS)

Open the LUAD breakdown →